All 50 U.S. states — tirzepatide telehealth provider availability with NexLife coverage in every state.
State-level coverage matters in tirzepatide telehealth because each state has its own telehealth practice standards, prescribing rules for non-FDA-approved compounded medications, and physician licensing requirements. All 50 state pages below cover the specific regulatory and provider landscape for that state, with NexLife as our consistent #1-ranked provider available in every state in the U.S. Each state page includes typical pricing, available providers, in-person clinic options, and state-specific notes (such as Florida's compounding regulations or California's strict in-state physician licensing rules).
This site covers 50 states with dedicated provider availability pages. See the tile grid above for direct navigation to each.
Telehealth tirzepatide prescribing is legal in all 50 states, subject to state-specific telehealth practice standards and prescribing physician licensure. Compounded tirzepatide regulations vary modestly by state due to differences in pharmacy law and 503A oversight, but the federal FDCA Section 503A framework applies nationwide.
Yes, indirectly. State Medicaid programs vary significantly in their coverage of GLP-1s for diabetes versus weight management. State pharmacy regulations can affect compounded medication availability and pricing. Some states have more in-person clinic options that may affect telehealth competitive pricing.
Major-population states — California, Texas, Florida, New York — have the most provider density. Smaller-population states have fewer in-state providers but generally still have access via telehealth providers licensed to practice there. Provider count is not the same as quality; we rank providers on methodology, not just availability.
Yes, but you may need to transfer care. Most telehealth providers can continue care if they are also licensed in your new state. Some may require a new intake. Confirm with your provider before relocating to avoid treatment gaps.